The world’s first multibacterial vaccine, Paragon Novel Vaccine (PNV), will receive 2.5 million euros (2.47 billion U.S. dollars) to advance clinical trials in humans.
The trials would assess the “safety, immunogenicity and initial efficacy” of the immunizer, which may receive a global investment of 17.5 million euros in the long term.
Previous reports said the vaccine can prevent infection from five different bacteria, including pneumococcus, calling the product “revolutionary.”
The PNV would “combat antibiotic-resistant bacteria associated with hospital-acquired infections that create very serious problems on a global scale,” said Immunethep co-founder and executive director Bruno Santos.
